223 related articles for article (PubMed ID: 38685841)
41. Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.
Monlish DA; Beezhold KJ; Chiaranunt P; Paz K; Moore NJ; Dobbs AK; Brown RA; Ozolek JA; Blazar BR; Byersdorfer CA
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34291733
[TBL] [Abstract][Full Text] [Related]
42. Adoptive transfer of H-2-incompatible lymphokine-activated killer (LAK) cells: an approach for successful cancer immunotherapy free from graft-versus-host disease (GVHD) using murine models.
Toshitani A; Taniguchi K; Himeno K; Kawano Y; Nomoto K
Cell Immunol; 1988 Sep; 115(2):373-82. PubMed ID: 3409329
[TBL] [Abstract][Full Text] [Related]
43. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
44. Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.
Rozmus J
Front Immunol; 2020; 11():574569. PubMed ID: 33613511
[TBL] [Abstract][Full Text] [Related]
45. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
46. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects.
Liang Y; Liu C; Djeu JY; Zhong B; Peters T; Scharffetter-Kochanek K; Anasetti C; Yu XZ
Blood; 2008 Jan; 111(2):954-62. PubMed ID: 17928532
[TBL] [Abstract][Full Text] [Related]
47. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
48. Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.
Fanning SL; Zilberberg J; Stein J; Vazzana K; Berger SA; Korngold R; Friedman TM
J Immunol; 2013 Jan; 190(1):447-57. PubMed ID: 23203931
[TBL] [Abstract][Full Text] [Related]
49. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.
Hippen KL; Hefazi M; Larson JH; Blazar BR
Front Immunol; 2022; 13():926550. PubMed ID: 35967386
[TBL] [Abstract][Full Text] [Related]
50. Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice.
Hu Y; Gu Y; Cui Q; Fu H; Sheng L; Wu K; Liu L; Fu S; Yu X; Huang H
Ann Hematol; 2012 Nov; 91(11):1803-12. PubMed ID: 22699803
[TBL] [Abstract][Full Text] [Related]
51. Intestinal graft-versus-host disease: mechanisms and management.
Takatsuka H; Iwasaki T; Okamoto T; Kakishita E
Drugs; 2003; 63(1):1-15. PubMed ID: 12487619
[TBL] [Abstract][Full Text] [Related]
52. Kinase Inhibition as Treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract][Full Text] [Related]
53. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
Peinemann F; Bartel C; Grouven U
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
[TBL] [Abstract][Full Text] [Related]
54. Graft-versus-host disease in bone marrow transplantation: experimental, laboratory, and clinical contributions of the last few years.
Kelemen E; Szebeni J; Petrányi GG
Int Arch Allergy Immunol; 1993; 102(4):309-20. PubMed ID: 8241794
[TBL] [Abstract][Full Text] [Related]
55. Graft-versus-host disease versus graft-versus-leukemia.
Negrin RS
Hematology Am Soc Hematol Educ Program; 2015; 2015():225-30. PubMed ID: 26637726
[TBL] [Abstract][Full Text] [Related]
56. Cyclosporine A but Not Corticosteroids Support Efficacy of
Landwehr-Kenzel S; Zobel A; Schmitt-Knosalla I; Forke A; Hoffmann H; Schmueck-Henneresse M; Klopfleisch R; Volk HD; Reinke P
Front Immunol; 2021; 12():716629. PubMed ID: 34707604
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
[TBL] [Abstract][Full Text] [Related]
58. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
[TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
[TBL] [Abstract][Full Text] [Related]
60. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
